The Association Between Sarcopenia and Diabetes: From Pathophysiology Mechanism to Therapeutic Strategy.

Content Provider	Europe PMC
Author	Chen, Huiling Huang, Xiaojing Dong, Meiyuan Wen, Song Zhou, Ligang Yuan, Xinlu
Copyright Year	2023
Abstract	AbstractDiabetes and sarcopenia are emerging as serious public health issues. Sarcopenia, an age-related disorder characterized by loss of skeletal muscle mass and function, is recognized as a new complication in elderly patients with type 2 diabetes mellitus (T2DM). Type 2 diabetes is characterized by insulin resistance, chronic inflammation, accumulation of advanced glycation products and increased oxidative stress, which can negatively affect skeletal muscle mass, strength and function leading to sarcopenia. There is a mutual interrelationship between T2DM and sarcopenia in light of pathophysiology mechanism and long-term outcome. T2DM will accelerate the decline of muscle mass and function, which will in turn lead to glucose metabolism disorders, reduced physical activity and the risk of diabetes. However, the specific mechanism involved has not been thoroughly studied. Therefore, this review aims to explore the pathophysiology and therapeutic strategy related to sarcopenia and diabetes and provide insight for future investigations, which is of great significance for improving the quality of life in the elderly with diabetes and concurrently reducing the incidence of related complications.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC10239259&blobtype=pdf
Page Count	14
Journal	Diabetes, Metabolic Syndrome and Obesity [Diabetes Metab Syndr Obes]
Volume Number	16
PubMed Central reference number	PMC10239259
PubMed reference number	37275941
e-ISSN	11787007
DOI	10.2147/dmso.s410834
Language	English
Publisher	Dove
Publisher Date	2023-05-30
Access Restriction	Open
Rights License	This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). © 2023 Chen et al.
Subject Keyword	type 2 diabetes mellitus sarcopenia insulin resistance inflammation gut microbiota therapeutic strategy
Content Type	Text
Resource Type	Article
Subject	Internal Medicine Pharmacology